# Vorinostat (SAHA) in Uterine Sarcoma

> **NCT03509207** · PHASE2 · TERMINATED · sponsor: **Medical University of Graz** · enrollment: 3 (actual)

## Conditions studied

- Leiomyosarcoma
- Endometrial Stromal Tumors
- Carcinosarcomas Uterine

## Interventions

- **DRUG:** Vorinostat Oral Capsule

## Key facts

- **NCT ID:** NCT03509207
- **Lead sponsor:** Medical University of Graz
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-12-14
- **Primary completion:** 2019-02-04
- **Final completion:** 2019-02-04
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** The early termination was NOT due to safety reasons, terminated because of the very slow recruitment and problematic access to the study medication in Europe
- **Last updated:** 2020-08-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03509207

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03509207, "Vorinostat (SAHA) in Uterine Sarcoma". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03509207. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*